Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

807.79 +3.17 (+0.39%)
Official Closing Price Updated: 7:00 PM EDT, Jul 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,473,686
Open 814.01
Bid (Size) 806.01 (1)
Ask (Size) 808.98 (1)
Prev. Close 804.62
Today's Range 804.00 - 824.77
52wk Range 446.89 - 966.10
Shares Outstanding N/A
Dividend Yield 0.56%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Eli Lilly’s $123 Billion Market Value Drop: A Strategic Buying Opportunity?
JPMorgan analyst says Eli Lilly will remain a leader in weight loss drugs. 
Via Talk Markets
3 Overlooked Stocks Poised for a Breakout Very Soon
Discover three overlooked breakout stocks with solid growth prospects, perfect for enhancing your investment portfolio. 
Via InvestorPlace

Performance

YTD
+36.40%
+36.40%
1 Month
-11.66%
-11.66%
3 Month
+9.58%
+9.58%
6 Month
+25.24%
+25.24%
1 Year
+77.71%
+77.71%

More News

Read More
Unpacking the Latest Options Trading Trends in Eli Lilly and Co
Via Benzinga
What Will Be the Best Weight Loss Drug Stock of 2030: Eli Lilly, or Novo Nordisk?
Via The Motley Fool
Weight Loss Drug Stocks Just Took a Hit. Should You Buy the Stock That Caused It?
Via The Motley Fool
Attention, Growth Investors: This Biotech Stock Is Crushing Nvidia.
Via The Motley Fool
Is Eli Lilly Stock a Buy?
Via The Motley Fool
Analyzing Eli Lilly and Co In Comparison To Competitors In Pharmaceuticals Industry
Via Benzinga
7 Smart Stocks to Buy BEFORE They Report Q2 Earnings
Via InvestorPlace
Home Depot Stock Turned $1,000 Into $17.5 Million, and One of Its Founders Just Revealed His Investing Secrets to Achieve Generational Wealth
Via The Motley Fool
Week In Review: Nanjing Triastek Partners With BioNTech In A $1.2 Billion Drug Development Deal
Via Talk Markets
Novo Nordisk's Next-Gen Diabetes Candidate Could Challenge Ozempic -- Is the Stock a Buy?
Via The Motley Fool
These 2 Growth Stocks Are Set to Soar This Summer and Beyond
Via The Motley Fool
Bull Market Buys: 2 Growth Stocks to Own for the Long Run
Via The Motley Fool
SPDR ETF Report For Friday, July 26
Via Talk Markets
Topics ETFs
Stock Market Diverges, With Tesla, Google, ServiceNow, GE In Focus: Weekly Review
Via Investor's Business Daily
Biogen/Eisai's Alzheimer's Drug Leqembi Gets 'No Go' From European Drug Regulator's Advisory Panel, Cites Serious Side Events
Via Benzinga
Biogen Stock Tumbles After European Regulators Unexpectedly Reject Alzheimer's Drug
Via Investor's Business Daily
Prediction: This Is What Eli Lilly Stock Will Do Next
Via The Motley Fool
Walt Disney, Eli Lilly, AST SpaceMobile, DexCom, Tesla: Why These 5 Stocks Are On Investors' Radars Today
Via Benzinga
Topics Stocks
Exposures US Equities
Why Weight Loss Drug Developer Stocks Tumbled on Thursday
Via The Motley Fool
7 Explosive Growth Stocks Set to Soar in 2024
Via InvestorPlace
Novo Nordisk Shares Decline Amid Competitive Pressure
Via Benzinga
3 Top-Performing Stocks Beating the Big Names in 2024
Via InvestorPlace
Viking Therapeutics Stock Surges As Company Advances Weight Loss Drug To Late-Stage Trial: What Investors Need To Know
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.